These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 2476882)

  • 1. High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response.
    Ferro MA; Gillatt D; Symes MO; Smith PJ
    Urology; 1989 Sep; 34(3):134-8. PubMed ID: 2476882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of prostate specific antigen in the baseline assessment of patients undergoing hormone therapy for advanced prostate cancer.
    Emtage LA; Lewis PW; Blackledge GR
    Br J Urol; 1987 Dec; 60(6):572-7. PubMed ID: 2447997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status?
    Leo ME; Bilhartz DL; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Apr; 145(4):802-6. PubMed ID: 1706440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements.
    Shih WJ; Wierzbinski B; Collins J; Magoun S; Chen IW; Ryo UY
    J Nucl Med; 1990 Sep; 31(9):1486-9. PubMed ID: 1697617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of high-dose fosfestrol in hormone-refractory adenocarcinoma of the prostate.
    Droz JP; De Smedt E; Kattan J; Keuppens F; Khoury S; Mahler C; Denis L
    Prostate; 1994; 24(2):62-6. PubMed ID: 7508621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer.
    Fosså SD; Waehre H; Paus E
    Br J Cancer; 1992 Jul; 66(1):181-4. PubMed ID: 1379059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM; Keller JJ; Bergstralh EJ; Oesterling JE
    J Urol; 1991 Feb; 145(2):313-8. PubMed ID: 1703240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate specific antigen for assessing response to ketoconazole and prednisone in patients with hormone refractory metastatic prostate cancer.
    Gerber GS; Chodak GW
    J Urol; 1990 Nov; 144(5):1177-9. PubMed ID: 1700145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantification of prostatic cancer metastatic disease using prostate-specific antigen.
    Vesey SG; Goble M; Ferro MA; Stower MJ; Hammonds JC; Smith PJ
    Urology; 1990 Jun; 35(6):483-6. PubMed ID: 1693796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.
    Miller JI; Ahmann FR; Drach GW; Emerson SS; Bottaccini MR
    J Urol; 1992 Mar; 147(3 Pt 2):956-61. PubMed ID: 1371568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose intravenous oestrogen (fosfestrol) in the treatment of symptomatic, metastatic, hormone-refractory carcinoma of the prostate.
    Ahmed M; Choksy S; Chilton CP; Munson KW; Williams JH
    Int Urol Nephrol; 1998; 30(2):159-64. PubMed ID: 9607886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of external beam radiation therapy on serum prostate-specific antigen.
    Chodak GW; Neumann J; Blix G; Sutton H; Farah R
    Urology; 1990 Apr; 35(4):288-94. PubMed ID: 1690936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Androgen-independent prostate cancer with bone metastasis successfully treated by intravenous administration of zoledronic acid and diethylstilbestrol diphosphate].
    Nishizawa S; Yamauchi T; Sawada Y
    Hinyokika Kiyo; 2007 Dec; 53(12):891-5. PubMed ID: 18203529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. IV. Anti-androgen treated patients.
    Stamey TA; Kabalin JN; Ferrari M; Yang N
    J Urol; 1989 May; 141(5):1088-90. PubMed ID: 2468797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of prostate-specific antigen after androgen withdrawal and prognosis in men with metastatic prostate cancer.
    Furuya Y; Akimoto S; Akakura K; Igarashi T; Murakami S; Shimazaki J; Ito H
    Urol Int; 1998; 60(1):28-32. PubMed ID: 9519418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer.
    Seidman AD; Scher HI; Petrylak D; Dershaw DD; Curley T
    J Urol; 1992 Mar; 147(3 Pt 2):931-4. PubMed ID: 1371564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen in management of prostatic carcinoma.
    Brawer MK; Lange PH
    Urology; 1989 May; 33(5 Suppl):11-6. PubMed ID: 2469244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma.
    Geller J
    Urol Clin North Am; 1991 Feb; 18(1):83-91. PubMed ID: 1825145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 89Strontium in bone metastases from hormone resistant prostate cancer: palliation effect and biochemical changes.
    Fosså SD; Paus E; Lochoff M; Backe SM; Aas M
    Br J Cancer; 1992 Jul; 66(1):177-80. PubMed ID: 1379058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up.
    Freitas JE; Gilvydas R; Ferry JD; Gonzalez JA
    J Nucl Med; 1991 Jul; 32(7):1387-90. PubMed ID: 1712383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.